EGFR and non-small cell lung carcinoma: Over the last years, liquid biopsy is widely used in oncogene-driven advanced and metastatic NSCLC to assess EGFR mutational status, either in first-line patients or after acquired resistance to EGFR TKIs (see Table 2 for details) [49,52,109,110,111,112,113].